8-K: Lumexa Imaging Reports Q1 2026 Results, Reaffirms Guidance

Lumexa Imaging announced its first quarter 2026 financial results, showing a 3.1% increase in consolidated revenues and a return to net income, while reiterating its full-year 2026 financial outlook.

Summary

• Lumexa Imaging reported first quarter 2026 consolidated revenues of $252.5 million, a 3.1% increase compared to $245.0 million in the same period last year.
• The company achieved a net income of $1.7 million for Q1 2026, a significant improvement from a net loss of $7.7 million in Q1 2025.
• Adjusted EBITDA was $51.2 million, a slight increase from $51.0 million in the prior year's quarter, with an Adjusted EBITDA margin of 20.3%.
• Same-center advanced imaging volumes grew by 5.6% for both consolidated and system-wide operations.
• The company announced four additional Lumexa Imaging centers, including two strategic tuck-in acquisitions and two de novo centers, progressing towards its goal of adding 8-10 de novo centers in 2026.
• Full-year 2026 guidance remains unchanged, with expected consolidated revenues between $1.045 billion and $1.097 billion, and Adjusted EBITDA between $234 million and $242 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with solid operational improvements and a return to profitability, but tempered by the impact of new public company costs on future growth metrics.

Positives

• Consolidated revenues increased by 3.1% to $252.5 million in Q1 2026.
• Shift from a net loss of $7.7 million in Q1 2025 to a net income of $1.7 million in Q1 2026.
• Strong same-center advanced imaging volume growth of 5.6%.
• Expansion of the center network with four new locations announced, supporting strategic growth objectives.
• Reiteration of full-year 2026 guidance, providing financial stability and predictability.

Negatives

• Adjusted EBITDA margin remained relatively flat at 20.3% compared to the prior year.
• The full-year Adjusted EBITDA guidance includes approximately $7 million in public company costs not incurred in 2025, which lowers the reported Adjusted EBITDA growth from 7% to 4% at the midpoint.
• Cash and cash equivalents decreased from $58.8 million at the end of 2025 to $51.2 million at the end of Q1 2026.

Risks

• The company's ability to achieve its stated goal of adding 8-10 de novo centers this year.
• Potential for future results to differ materially from projections due to risks and uncertainties identified in the Form 10-K.
• The impact of public company costs on future profitability.
• Uncertainty and potential variability of reconciling items for non-GAAP guidance, such as transaction costs and severance.

Future Outlook

Lumexa Imaging is reiterating its full-year 2026 guidance, expecting consolidated revenues between $1.045 billion and $1.097 billion, and Adjusted EBITDA between $234 million and $242 million. The guidance includes approximately $7 million in public company costs not present in 2025, which impacts reported Adjusted EBITDA growth.

Management Comments

• "In Q1, we delivered several meaningful achievements to kick off a year of executing on our strategic priorities."
• "We continued to drive strong growth in same-center advanced imaging volumes and our de novo centers are ramping according to our plans."
• "With a large addressable market, and strong demand tailwinds plus a focused strategy centered on same-center growth, geographic expansion, and advanced imaging, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors."

Industry Context

StockSavvy.ai notes that Lumexa Imaging's Q1 2026 results reflect continued growth in outpatient imaging services, a sector benefiting from demand for convenient and cost-effective diagnostic procedures. The company's focus on same-center growth and expansion through de novo centers and acquisitions aligns with industry trends of consolidation and strategic geographic positioning.

Comparison to Industry Standards

• The 3.1% consolidated revenue growth is moderate compared to some high-growth healthcare sub-sectors, but aligns with mature outpatient service providers.
• The 5.6% same-center advanced volume growth indicates strong organic performance, outperforming general market growth for imaging services.
• The shift to profitability (net income of $1.7 million) is a positive sign, though the Adjusted EBITDA margin of 20.3% needs to be benchmarked against peers like RadNet or Envision Healthcare for a complete picture.

Related Party Transactions

• Accounts receivable, related party: $15,942 thousand as of March 31, 2026, down from $18,893 thousand at December 31, 2025.

Stakeholder Impact

• Shareholders: Reiteration of guidance and return to profitability may support stock value, but impact of public company costs needs monitoring.
• Employees: Continued expansion and focus on strategic priorities suggest ongoing operational activity and potential for growth.
• Patients/Providers/Payors: Company aims to expand access to high-quality, lower-cost imaging services.

Next Steps

• Continue executing on strategic priorities for 2026.
• Achieve the stated goal of adding 8-10 de novo centers to the network.
• Host conference call and webcast on May 12, 2026, to discuss Q1 results and 2026 outlook.

Key Dates

Recommendation

The company demonstrated a return to profitability and solid operational execution in Q1 2026, with strong same-center growth. However, the moderate overall revenue growth, flat Adjusted EBITDA margin, and the impact of new public company costs on future guidance suggest a 'hold' recommendation pending further evidence of accelerated growth or margin expansion.

Keywords

Lumexa Imaging, 8-K, Q1 2026 Results, Financial Results, Outpatient Imaging, Adjusted EBITDA, Revenue Growth, Guidance